Glenmark Life Sciences reports robust 25% EBITDA growth in Q1FY24
The net profit in the June quarter was also lower than Rs 146.3 crore reported in the March quarter.
The net profit in the June quarter was also lower than Rs 146.3 crore reported in the March quarter.
The newly launched Genomic Health Insights (GHI) program to make sequencing accessible to all
Shareholding of the company in MIMS has increased from 76.01 per cent to 78.37 per cent
Acquisition delivers industry-leading research capability, and strengthens pipeline with a novel candidate for ulcerative colitis, Crohn’s disease and other autoimmune conditions
Suven Life Sciences completed enrollment of patients to the phase-2, PoC clinical study of samelisant (SUVN-G3031) for the treatment of narcolepsy with or without cataplexy in USA and Canada
Eris Lifesciences has reported total income of Rs. 403.80 crores during the period ended March 31, 2023
He has over two decades of leadership experience as an innovative strategic planner in finance diligence
The consolidated EBITDA stood at Rs. 89.3 crore in FY23 as compared to Rs. 164.5 crore in the same period last year
Revenue from operations at Rs 512.81 crores registered a growth of 17% Y-o-Y for full year FY23
Subscribe To Our Newsletter & Stay Updated